Literature DB >> 12350389

Characteristics of epilepsy in focal cortical dysplasia in infancy.

Anne Lortie1, Perrine Plouin, Catherine Chiron, Olivier Delalande, Olivier Dulac.   

Abstract

To describe the poorly known characteristics of epilepsy during infancy in focal cortical dysplasia (FCD), one of the most frequent cause of infantile epilepsy. All 28 patients with FCD referred to two specialized centres were retrospectively studied regarding seizure characteristics, psychomotor evaluation, and response to medical and surgical treatment. All patients presented with early partial seizures. Semiology, but not the age of onset, depended on the topography of the dysplasia, with abnormal eye movements in all cases of posterior FCD. Eleven patients also developed infantile spasms (IS), mainly asymmetrical. IS were easily controlled with Vigabatrin or ACTH, but no partial seizures could be medically controlled except in one patient. All patients except one had abnormal neuropsychological findings. Fifteen patients had surgery, eight became seizure free, and seven were significantly improved regarding psychomotor development. Very early and refractory partial seizures, but easily controlled IS are the main characteristics of FCD in infancy. Only the focal ictal semiology may help differentiate the localization of FCD. Its intrinsic epileptogenicity could sustain this clinical pattern. Since the chances for medical control and normal neurodevelopment are poor, surgical treatment should be considered early in infants with FCD. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Year:  2002        PMID: 12350389     DOI: 10.1016/s0920-1211(02)00102-x

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  8 in total

Review 1.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

2.  Type II focal cortical dysplasia: electroclinical study and surgical outcome in 31 pediatric patients.

Authors:  Daniel Noli; Marcelo Bartuluchi; Federico Sanchez González; María Carolina Kaltenmeier; Ricardo Cersosimo; Carlos Rugilo; Juan P Princich; Fabiana Lubieniecki; Hugo Pomata; Roberto Caraballo
Journal:  Childs Nerv Syst       Date:  2013-07-07       Impact factor: 1.475

Review 3.  Surgery for posterior quadrantic cortical dysplasia. A review.

Authors:  G Tamburrini; D Battaglia; E Albamonte; I Contaldo; L Massimi; M Caldarelli; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2014-10-09       Impact factor: 1.475

Review 4.  Pharmacotherapy for Focal Seizures in Children and Adolescents.

Authors:  Clare E Stevens; Carl E Stafstrom
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

5.  Etiologic classification of infantile spasms using positron emission/magnetic resonance imaging and the efficacy of adrenocorticotropic hormone therapy.

Authors:  Haodan Dang; Liping Zou; Jiahe Tian; Jiajin Liu; Xiang Feng; Mu Lin; Baixuan Xu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-03       Impact factor: 9.236

6.  Clinical features and surgical outcomes in young children with focal cortical dysplasia type II.

Authors:  Tian-Shuang Wang; Qing-Zhu Liu; Ming Liu; Qian Zhang; Ruo-Fan Wang; Chong-Wei Wu; Jie Zhang; Wen Wang; Tao-Yun Ji; Xiao-Yan Liu; Shuang Wang; Li-Xin Cai; Yu-Wu Jiang; Ye Wu
Journal:  CNS Neurosci Ther       Date:  2019-08-01       Impact factor: 5.243

Review 7.  Neuropsychological features of lesion-related epilepsy in adults: an overview.

Authors:  Chris E Morrison; Luba Nakhutina
Journal:  Neuropsychol Rev       Date:  2007-10-19       Impact factor: 6.940

8.  GABAA Receptor-Mediated Epileptogenicity in Focal Cortical Dysplasia (FCD) Depends on Age at Epilepsy Onset.

Authors:  Jyotirmoy Banerjee; Soumil Dey; Aparna Banerjee Dixit; Ramesh Doddamani; Meher Chand Sharma; Ajay Garg; P Sarat Chandra; Manjari Tripathi
Journal:  Front Cell Neurosci       Date:  2020-09-30       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.